000277726 001__ 277726
000277726 005__ 20250403095900.0
000277726 0247_ $$2doi$$a10.1002/mds.30086
000277726 0247_ $$2pmid$$apmid:39665525
000277726 0247_ $$2pmc$$apmc:PMC11926492
000277726 0247_ $$2ISSN$$a0885-3185
000277726 0247_ $$2ISSN$$a1531-8257
000277726 037__ $$aDZNE-2025-00447
000277726 041__ $$aEnglish
000277726 082__ $$a610
000277726 1001_ $$0P:(DE-2719)9000983$$aPeikert, Kevin$$b0
000277726 245__ $$aPhosphatidylethanolamines are the Main Lipid Class Altered in Red Blood Cells from Patients with VPS13A Disease/Chorea-Acanthocytosis.
000277726 260__ $$aNew York, NY$$bWiley$$c2025
000277726 3367_ $$2DRIVER$$aarticle
000277726 3367_ $$2DataCite$$aOutput Types/Journal article
000277726 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1743593170_4325
000277726 3367_ $$2BibTeX$$aARTICLE
000277726 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000277726 3367_ $$00$$2EndNote$$aJournal Article
000277726 520__ $$aVPS13A disease is an ultra-rare disorder caused by loss of function mutations in VPS13A characterized by striatal degeneration and by red blood cell (RBC) acanthocytosis. VPS13A is a bridge-like protein mediating lipid transfer at membrane contact sites.To assess the lipid composition of patient-derived RBCs.RBCs collected from 5 VPS13A disease patients and 12 control subjects were analyzed by mass spectrometry (lipidomics).While we found no significant differences in the overall lipid class level, alterations in certain species were detected: phosphatidylethanolamine species with both longer chain length and higher unsaturation were increased in VPS13A disease samples. Specific ceramide, phosphatidylcholine, and sphingomyelin species were also altered.The presented alterations of particular lipid species in RBCs in VPS13A disease may contribute to (1) the understanding of acanthocyte formation, and (2) future biomarker identification. Lipid distribution seems to play a key role in the pathophysiology of VPS13A disease. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
000277726 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000277726 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000277726 650_7 $$2NLM Chemicals$$aVPS13A protein, human
000277726 650_7 $$2NLM Chemicals$$aPhosphatidylethanolamines
000277726 650_7 $$2NLM Chemicals$$aVesicular Transport Proteins
000277726 650_2 $$2MeSH$$aHumans
000277726 650_2 $$2MeSH$$aNeuroacanthocytosis: genetics
000277726 650_2 $$2MeSH$$aNeuroacanthocytosis: metabolism
000277726 650_2 $$2MeSH$$aNeuroacanthocytosis: blood
000277726 650_2 $$2MeSH$$aNeuroacanthocytosis: pathology
000277726 650_2 $$2MeSH$$aPhosphatidylethanolamines: metabolism
000277726 650_2 $$2MeSH$$aErythrocytes: metabolism
000277726 650_2 $$2MeSH$$aMale
000277726 650_2 $$2MeSH$$aVesicular Transport Proteins: genetics
000277726 650_2 $$2MeSH$$aVesicular Transport Proteins: metabolism
000277726 650_2 $$2MeSH$$aFemale
000277726 650_2 $$2MeSH$$aAdult
000277726 650_2 $$2MeSH$$aMiddle Aged
000277726 650_2 $$2MeSH$$aLipidomics: methods
000277726 650_2 $$2MeSH$$aAcanthocytes: metabolism
000277726 650_2 $$2MeSH$$aAcanthocytes: pathology
000277726 7001_ $$aSpranger, Adrian$$b1
000277726 7001_ $$00000-0003-0224-1281$$aMiltenberger-Miltenyi, Gabriel$$b2
000277726 7001_ $$aGlaß, Hannes$$b3
000277726 7001_ $$0P:(DE-2719)2814178$$aFalkenburger, Björn$$b4$$udzne
000277726 7001_ $$aKlose, Christian$$b5
000277726 7001_ $$aTyteca, Donatienne$$b6
000277726 7001_ $$0P:(DE-2719)2811732$$aHermann, Andreas$$b7$$eLast author
000277726 773__ $$0PERI:(DE-600)2041249-6$$a10.1002/mds.30086$$gVol. 40, no. 3, p. 544 - 549$$n3$$p544 - 549$$tMovement disorders$$v40$$x0885-3185$$y2025
000277726 8564_ $$uhttps://pub.dzne.de/record/277726/files/DZNE-2025-00447%20SUP1.docx
000277726 8564_ $$uhttps://pub.dzne.de/record/277726/files/DZNE-2025-00447%20SUP2.xlsx
000277726 8564_ $$uhttps://pub.dzne.de/record/277726/files/DZNE-2025-00447%20SUP3.pdf
000277726 8564_ $$uhttps://pub.dzne.de/record/277726/files/DZNE-2025-00447.pdf$$yOpenAccess
000277726 8564_ $$uhttps://pub.dzne.de/record/277726/files/DZNE-2025-00447%20SUP1.doc
000277726 8564_ $$uhttps://pub.dzne.de/record/277726/files/DZNE-2025-00447%20SUP1.odt
000277726 8564_ $$uhttps://pub.dzne.de/record/277726/files/DZNE-2025-00447%20SUP1.pdf
000277726 8564_ $$uhttps://pub.dzne.de/record/277726/files/DZNE-2025-00447%20SUP2.csv
000277726 8564_ $$uhttps://pub.dzne.de/record/277726/files/DZNE-2025-00447%20SUP2.ods
000277726 8564_ $$uhttps://pub.dzne.de/record/277726/files/DZNE-2025-00447%20SUP2.xls
000277726 8564_ $$uhttps://pub.dzne.de/record/277726/files/DZNE-2025-00447%20SUP3.pdf?subformat=pdfa$$xpdfa
000277726 8564_ $$uhttps://pub.dzne.de/record/277726/files/DZNE-2025-00447.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000277726 909CO $$ooai:pub.dzne.de:277726$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000277726 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2814178$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000277726 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811732$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000277726 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000277726 9141_ $$y2025
000277726 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-16
000277726 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-16
000277726 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-16
000277726 915__ $$0LIC:(DE-HGF)CCBYNCND4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
000277726 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMOVEMENT DISORD : 2022$$d2024-12-16
000277726 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2024-12-16$$wger
000277726 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-16
000277726 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-16
000277726 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-16
000277726 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000277726 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-16
000277726 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bMOVEMENT DISORD : 2022$$d2024-12-16
000277726 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-16
000277726 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-16
000277726 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-16$$wger
000277726 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-16
000277726 9201_ $$0I:(DE-2719)1511100$$kAG Hermann$$lTranslational Neurodegeneration$$x0
000277726 9201_ $$0I:(DE-2719)1710012$$kAG Falkenburger$$lTranslational Parkinson Research$$x1
000277726 980__ $$ajournal
000277726 980__ $$aVDB
000277726 980__ $$aUNRESTRICTED
000277726 980__ $$aI:(DE-2719)1511100
000277726 980__ $$aI:(DE-2719)1710012
000277726 9801_ $$aFullTexts